Strata Critical Medical, Inc. Q3 FY2026 earnings call

• Strategic Transformation: One year post-strategic transformation, Strata demonstrates strong cash generation ($8.6 million free cash flow) and market share gains through its integrated transplant offering.
• Integrated Platform Efficiency: The company leverages an integrated platform (recovery, perfusion, logistics, placement) to manage complex DCD donors. This reduces 'dry run' costs and allows for higher surgeon utilization via local commercial travel.
• Market Share Gains: Clinical segment gained share despite a 7% sequential drop in industry transplant volumes, driven by superior efficiency and customer alignment.
• New Business Line: Launched cardiothoracic surgical locum tenens services in October to increase surgeon utilization, improve retention, and expand the total addressable market.
• M&A Execution: Closed over $6 million of expected annualized adjusted EBITDA in 2026 at mid-single-digit multiples, well ahead of plan, with a strong pipeline for future deployments.
• Financial Health: Ended quarter with ~$42 million in cash/short-term investments, bolstered by the first passenger sale earn-out ($15.3 million net proceeds), enabling accelerated M&A and shareholder returns.

Total revenue increased 50.3% to $74.1 million in Q3 2026, driven by clinical segment growth and acquisitions, partially offset by logistics declines. Clinical revenue grew 20.3% sequentially, with gross profit increasing 18.3% sequentially; however, clinical gross margin declined 50 basis points to 25.6% due to staffing investments and part-time provider usage. Logistics revenue decreased 6.9% sequentially, aligning with seasonal industry declines, but logistics gross margin rebounded significantly by 240 basis points to 20.8%, outperforming the 20% target ahead of schedule.

• Reiterated full-year 2026 guidance: Revenue of $285–$295 million, Adjusted EBITDA of $33–$35 million, and Free Cash Flow (before aircraft/engine acquisitions) of $15–$22 million.
• Q4 2026 Outlook: Expects low single-digit sequential revenue increase, driven primarily by clinical growth as logistics remains flat due to lack of typical seasonal pickup.
• Margin Expectations: Gross margin expected to remain flat sequentially in Q4, with anticipated improvement in clinical margins in 2027 as dedicated resources replace part-time providers.
• Medium-Term Targets: Confident in achieving high-teens organic Adjusted EBITDA growth and 30%+ total Adjusted EBITDA growth (including acquisitions) in 2027.
• Capital Allocation: No material capital allocation for aircraft purchases expected in the near term; focus remains on M&A and opportunistic share repurchases.

• Regulatory Policy Changes: Modifications to organ allocation policies (e.g., lung continuous distribution adjustments) cause volatility in trip distances and volumes, impacting logistics revenue.
• Seasonal Volatility: Transplant volumes exhibit significant seasonality and month-to-month volatility, which can obscure underlying business trends.
• Operational Complexity: Increased reliance on DCD donors and perfusion technology introduces complexity and higher 'dry run' rates (~30%), requiring robust integrated solutions.
• Competitive Landscape: Potential competition from OPO decertifications or regional providers, though Strata mitigates this via national scale and integrated offerings.
• Non-Cash Accounting Items: Current GAAP losses are driven by non-cash items such as intangible asset amortization and earn-out revaluations, which may distort short-term profitability perceptions.

Q: Analyst asked about the impact of the new OPO rule and lung distance changes on revenue concentration and long-term trends.

A: Co-CEO Will Heyburn stated that Strata has minimal exposure (<3%) to Tier 3 OPOs, reducing decertification risk. Regarding lungs, he noted that while recent OPTN tweaks caused a slight reduction in distances, the long-term trend toward continuous distribution is positive, likely leading to more transplants and longer distances over time, positioning Strata favorably.

Q: Analyst asked about the drivers behind the projected 80% NRP adoption rate for DCD donors by 2028 and differences between US and EU markets.

A: Co-CEO Melissa Tomkiel explained that European trends inspire confidence in widespread NRP adaptation. In the US, regulatory shifts including CMS changes and inevitable OPO consolidation are accelerating this trend, driving the estimate toward 80% adoption by 2028.

Q: Analyst inquired about the split of organic growth in the clinical segment and future growth prospects for transplant vs. other clinical lines.

A: Co-CEO Will Heyburn clarified that like-for-like year-over-year clinical growth exceeded 30%. He emphasized that faster growth remains weighted toward the transplant clinical business, which benefits from the integrated model's ability to handle complex cases and drive higher-value transactions.

Q: Analyst asked if the launch of the locum tenens business changes M&A tactics and if Strata needs fewer planes or will own more in the future.

A: Co-CEO Melissa Tomkiel stated the locum business entrenches customer relationships and improves surgeon retention without altering the open M&A strategy. Regarding assets, she confirmed no need for additional owned planes to scale efficiently, relying instead on strategic fleet location and non-owned capacity for flexibility.

Q: Analyst asked about the timing of share buybacks and whether future acquisitions would differ in size/type given the stronger balance sheet.

A: Co-CEO Will Heyburn explained the buyback is opportunistic due to excess cash from earn-outs and ahead-of-plan M&A execution. He reiterated that future deals will follow the established mid-single-digit EBITDA multiple framework, focusing on tuck-ins that enhance existing successful businesses rather than changing deal sizes fundamentally.